Non-Invasive Prenatal Screening (NIPS)
- Also Known As:
- Non-Invasive Prenatal Testing
- Cell-Free Fetal DNA
- Formal Name:
- Cell-Free DNA Prenatal Screen for Fetal Aneuploidy
At a Glance
Why Get Tested?
For pregnant women, to assess the risk of your developing baby (fetus) having certain chromosome disorders
When To Get Tested?
During or after the 10th week of pregnancy
A blood sample drawn from a vein in the mother’s arm
Test Preparation Needed?
What is being tested?
Non-invasive prenatal screening (NIPS) helps determine the risk that a pregnant woman’s developing baby (fetus) has a chromosome disorder. It is not a diagnostic test, meaning it cannot tell for certain whether your baby is affected or unaffected. If NIPS shows an increased risk for a specific chromosome disorder, diagnostic testing by chorionic villus sampling (CVS) or amniocentesis is recommended to establish the true diagnosis.
NIPS evaluates a type of genetic material called cell-free DNA (cfDNA) that is released by cells from the placenta and circulates in the mother’s blood during pregnancy. The cfDNA from the placenta generally reflects the genetic makeup of the developing baby (fetus). NIPS detects chromosome disorders in placental cfDNA and can be performed as early as the 10th week of pregnancy.
Although there are many similarities among various versions of NIPS, laboratories may offer opt-in or opt-out choices for things like the sex chromosomes or microdeletions. It is important to speak to your healthcare practitioner about which test is being recommended for you. NIPS may screen for:
- The presence of extra chromosomes (trisomies) such as:
- Down syndrome (trisomy 21)—Down syndrome is the most common of the three trisomies screened for by NIPS. While all individuals with Down syndrome share certain characteristics, the severity of these characteristics can vary quite broadly.
- Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13) are both less common than Down syndrome and typically much more severe. Many babies with Edwards or Patau syndrome do not survive to the first year.
- Sex chromosome disorders—some people elect to have the sex chromosomes screened to learn the anticipated sex of their baby, but there are also sex chromosome disorders, such as Turner syndrome, Klinefelter syndrome and XXX syndrome that may be identified.
- Microdeletion syndromes—although not recommended by professional guidelines, some laboratories also offer screening for a set of disorders caused by small missing segments of specific chromosomes, called microdeletion syndromes. When chromosomal segments are missing, differences in the amount of chromosomal information present alter the baby’s development and cause the features of these disorders. With the exception of DiGeorge syndrome (also called deletion 22q11.2 syndrome), the other conditions are quite rare, and the test’s ability to correctly identify microdeletions is unclear.
How is the test used?
Non-invasive prenatal screening (NIPS) may be used to assess the risk of a pregnant woman’s developing baby (fetus) having a chromosome disorder, such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), or Patau syndrome (trisomy 13). It may also be used to identify sex chromosome abnormalities (changes to the number of X or Y chromosomes present). Some laboratories offer additional testing for conditions caused by small segments of missing information on specific chromosomes, called microdeletion syndromes.
You should discuss this and other screening options with your health care practitioner to ensure it is the best choice for you. If you are not certain which prenatal screening or diagnostic test is right for you, it may be a good idea to speak with a genetic counselor.
When is it ordered?
The non-invasive prenatal screening (NIPS) can be offered during or after the tenth week of pregnancy. Samples collected prior to this time are automatically rejected, so it is important to be certain that the pregnancy is at a minimum of 10 weeks along.
What does the test result mean?
Results may be reported as “low risk” (negative) or “high risk” (positive).
A NIPS result that is reported as “negative” or as “low risk” means that it is unlikely the baby has any of the specific chromosome disorders that were screened. Most NIPS tests evaluate the risk for Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13), but depending on how your healthcare practitioner ordered the test, it may also include the sex chromosomes (X and Y) and certain microdeletion syndromes.
It is important to remember that NIPS is a screening test, not a diagnostic test, so it is possible that the baby actually has a chromosomal disorder, even though the screening results show low risk (a false-negative result). In addition, NIPS does not screen every chromosome and does not detect the many genetic disorders that are caused by smaller changes in DNA. This means that other chromosome abnormalities or genetic disorders could be present and would not be identified by NIPS.
A NIPS result that is reported as “positive” or “increased/high risk” means that the baby is at an increased risk of having the abnormality identified. It is important to note that, while the test’s ability to correctly identify pregnancies at increased risk of Down syndrome is high, it is not as good at correctly identifying abnormalities of other chromosomes, including 18, 13 and X. It is important to remember that NIPS is a screening test and not a diagnostic test, so it is possible that the baby actually does not have the disorder indicated (false-positive result).
Diagnostic testing can be performed with either chorionic villus sampling (CVS), which samples placental tissue, between the 10th and 13th week of pregnancy, or amniocentesis (amnio), which samples amniotic fluid, after about 16 weeks of pregnancy. Chromosomal analysis by karyotyping or chromosomal microarray is performed on the sample to rule out or confirm a suspected chromosome disorder.
In some cases, the laboratory that performs the NIPS testing will return an “indeterminate” or “no call” result when there is an insufficient amount of cfDNA from the placenta in the mother’s blood sample. There are a number of factors that may affect this measurement, such as the gestational age, the presence of multiple fetuses (e.g., twins) and the mother’s weight. Obese women tend to have a lower concentration of placental cfDNA in their bloodstream.
American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recommend that women with a “no call” result be offered diagnostic testing using CVS or amniocentesis rather than repeating the NIPS testing (unless the sample was accidentally collected too early in the pregnancy). For mothers who are obese, their health care practitioner may offer a prenatal screen that is less affected by maternal weight than NIPS.
There are different versions of NIPS offered by different laboratories. Healthcare practitioners should be prepared to offer pre- and post-test genetic counseling for the version of NIPS that are chosen for their patients. If there are additional questions about result interpretation, a referral to a maternal-fetal medicine specialist and/or genetic counselor is appropriate.
Should I ask my health care practitioner about having NIPS performed?
NIPS that uses cfDNA testing is only one of the options that may be offered for prenatal screening for chromosome disorders and it may not be routinely offered by your health care practitioner. If you are interested in NIPS, you may choose to discuss it as well as other options with your health care practitioner to make an informed decision. You may also be referred to a genetic counselor to help you better understand the limitations and benefits of screening as well as the significance of a “screen positive” versus a “screen negative” result.
Besides NIPS, what are the other options for prenatal screening?
Other options include:
- First trimester maternal serum screening—includes an ultrasound exam to measure the thickness of a space at the back of the fetus’s neck (nuchal translucency) and blood tests to measure pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG).
- Second trimester maternal serum screening—includes blood tests for alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol (triple screen) or includes those three tests plus inhibin A (quad screen).
- Integrated screening, which combines first and second trimester screening results.
If any of these screening tests are positive for an increased risk of a chromosomal disorder, the recommendation is to offer diagnostic testing by CVS or amniocentesis. It is not recommended to perform multiple screening tests, so while NIPS is sometimes offered following a positive serum screen result, the appropriate course of action is to offer diagnostic testing.
The screening approach a woman chooses depends on her preferences, what technology is available through her health care practitioner or local hospital, as well as when she first seeks prenatal care.
Ultimately, you should discuss available prenatal screening and diagnostic testing options with your health care provider or a genetics specialist, such as a genetic counselor. Post-test genetic counseling for women with a positive screening or diagnostic result is recommended.
If I have a negative NIPS with my current pregnancy, will I need to repeat it with the next baby?
NIPS may be a screening option for you in any of your pregnancies. Since it is the baby’s placental cfDNA that is being assessed, each pregnancy is evaluated separately.
How long does it take for NIPS results?
Results are typically available in less than one week, but different laboratories have different result turn-around times, so it is best to check with the lab performing your NIPS.
Does NIPS test for open neural tube defects such as spina bifida?
No. NIPS cannot detect open neural tube defects or abdominal wall defects. Screening for these conditions is typically performed by a detailed ultrasound in the second trimester as well as a second trimester blood test called alpha-fetoprotein (AFP) serum screening (Second Trimester Maternal Serum Screening).
Will this test tell me the sex of my baby?
It depends on the type of NIPS your health care practitioner orders and the specific lab that does the testing. Many laboratories routinely offer screening for five chromosomes: 21, 18, 13, X and Y. If this is the case, NIPS will show you the predicted sex of your baby. Remember that false negatives and false positives occur in screening tests. If you do not want to know the predicted sex of your baby, it might be possible for the lab to only report on the sex chromosomes if there is a sex chromosome abnormality (but not if it is a normal male or a normal female). If not, you can request that a note is placed in your file indicating that you do not want to know the baby’s sex.
Sources Used in Current Review
ACOG Committee Opinion 640. Cell-free DNA Screening for fetal aneuploidy. Obstet Gynecol. 2015 Sept;126:31-37 2.
ACOG Committee on Genetics: Committee Opinion No. 682. Microarrays and Next-Generation Sequencing Technology: The Use of Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. Obstet Gynecol. 2016;128(6):1462-1463 3.
ACOG Practice Bulletin No. 163: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2016;127:123-137.
National Society of Genetic Counselors Position Statements: Prenatal Cell-Free DNA Screening. Released 10-11-16, updated 4-12-18. Available online at https://www.nsgc.org/p/bl/et/blogaid=805.
(April 29, 2016) Mark W Leach, ACOG Issues New Prenatal Testing Guidelines. Available online at https://prenatalinformation.org/2016/04/29/acog-issues-new-prenatal-testing-guidelines/ Accessed February 2020.
© 1995–2020 Mayo Clinic Laboratories. Cell-Free DNA Prenatal Screen, Blood. Available online at https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/63439. Accessed February 2020.
© 1995–2020 Mayo Clinic Laboratories. Cell-Free DNA Prenatal Screen, Autosomal Trisomy and Sex Chromosome Aneuploidy, Blood. Available online at https://www.mayocliniclabs.com/test-catalog/Overview/65518. Accessed February 2020.
© 2019 ARUP Laboratories. Non-Invasive Prenatal Testing for Fetal Aneuploidy. Available online at http://ltd.aruplab.com/Tests/Pub/2007537. Accessed February 2020.
(September 2019) American College of Obstetricians and Gynecologists. Prenatal Genetic Screening Tests. Available online at https://www.acog.org/Patients/FAQs/Prenatal-Genetic-Screening-Tests. Accessed February 2020.
Sources Used in Previous Reviews
Lewis, R. (2014 February 27). Noninvasive Prenatal DNA Test Okay for Low-Risk Pregnancies. Medscape Medical News [On-line information]. Available online at http://www.medscape.com/viewarticle/821213. Accessed March 2014.
Lewis, R. (2014 March 8). Fetal DNA Testing for Low-Risk Women Gets Mixed Reviews. Medscape Medical News [On-line information]. Available online at http://www.medscape.com/viewarticle/821690. Accessed March 2014.
(2014 March). Non-invasive Prenatal Testing for Chromosomal Abnormality using Maternal Plasma DNA. Royal College of Obstetricians and Gynaecologists Scientific Impact Paper No. 15 [On-line information]. Available online at http://www.rcog.org.uk/files/rcog-corp/SIP_15_04032014.pdf. Accessed March 2014.
(2014 March 5). SMFM Physicians Recommend NIPT for High-Risk Patients. Smfm Newsroom [On-line information]. Available online at http://www.smfmnewsroom.org/2014/03/smfm-physicians-recommend-nipt-for-high-risk-patients/. Accessed March 2014.
Bianchi, D. et. al. (2014 February 27). DNA Sequencing versus Standard Prenatal Aneuploidy Screening. N Engl J Med 2014; 370:799-808 Preview [On-line information]. Available online at http://www.nejm.org/doi/full/10.1056/NEJMoa1311037. Accessed March 2014.
(2012 August 28). Fetal fraction of cfDNA does not vary significantly among pregnant women regardless of trisomy risk. News Medical [On-line information]. Available online through http://www.news-medical.net. Accessed March 2014.
Barclay, L. (2013 June 7). Maternal Blood Test May Detect Trisomy in First Trimester. Medscape Medical News [On-line information]. Available online at http://www.medscape.com/viewarticle/805519. Accessed March 2014.
(2012 October 3). Cell-Free DNA Test Highly Accurate as Prenatal Screen. Medscape Multispecialty from Reuters Health Information [On-line information]. Available online at http://www.medscape.com/viewarticle/771926. Accessed March 2014.
Laura A. Stokowski, L. and Klugman, S. (2013 November 7). The Pros and Cons of Noninvasive Prenatal Screening. Medscape Multispecialty [On-line information]. Available online at http://www.medscape.com/viewarticle/813882. Accessed March 2014.
Walsh, J. (2012 June 20). Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing. Medscape Multispecialty from CTAF [On-line information]. Available online at http://www.medscape.com/viewarticle/773416. Accessed March 2014.
(Reviewed 2013 July). Prenatal Tests. March of Dimes [On-line information]. Available online at http://www.marchofdimes.com/pregnancy/prenatal-tests.aspx#. Accessed March 2014.
Brock, J. and Langlois, S. (2013 February). Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma. SOGC Clinical Practice Guidelines [On-line information]. Available online through http://sogc.org. Accessed March 2014.
Lynch, E. and Dezen, T. (2012 December 12). The Leading Edge Of Medical Innovation: New Prenatal Genetic Tests Use Mom’s Blood to Learn about Her Baby. March of Dimes [On-line information]. Available online through http://www.marchofdimes.com. Accessed March 2014.
(Reviewed 2013 November). Trisomy 13. Genetics Home Reference [On-line information]. Available online at http://ghr.nlm.nih.gov/condition/trisomy-13. Accessed April 2014.
Elshimali, Y. et. al. (2013 September 13). The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients. Int J Mol Sci. Sep 2013; 14(9): 18925–18958. [On-line information]. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794814/. Accessed April 2014.
(December 2012) The American College of Obstetricians and Gynecologists Committee on Genetics, The Society for Maternal-Fetal Medicine Publications Committee, Noninvasive Prenatal Testing for Fetal Aneuploidy. Available online through http://www.acog.org. Accessed May 2014.
Gregg AR, Skotko, BG, Bekendorf JL, et al. Noninvasive Prenatal Screening for Fetal Aneuploidy, 2016 Update: A Position Statement of the American College of Medical Genetics and Genomics. Genetics In Medicine. Published online 28 July 2016. Available online at http://www.nature.com/gim/journal/vaop/ncurrent/full/gim201697a.html. Accessed January 10, 2017.
Genetic Support Foundation. Cell-free DNA (cfDNA) Screening. Available online at https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/pregnancy-and-genetics-tests/cell-free-dna-cfdna. Accessed January 2017.
(September 2016) American College of Obstetricians and Gynecologists. Prenatal Genetic Screening Tests. Available online at http://www.acog.org/Patients/FAQs/Prenatal-Genetic-Screening-Tests?IsMobileSet=false. Accessed January 2017.
(©2017) Cell-Free DNA Prenatal Screen. Mayo Medical Laboratories. Available online at http://www.mayomedicallaboratories.com/test-catalog/Specimen/63439. Accessed January 2017.
(September 2015) American College of Obstetricians and Gynecologists. Committee on Genetics Society for Maternal–Fetal Medicine, Committee Opinion No. 640. Available online at http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Genetics/Cell-free-DNA-Screening-for-Fetal-Aneuploidy. Accessed January 2017.
(September 2016) Prenatal Genetic Screening Tests. American Congress of Obstetricians and Gynecologists. Available online at http://www.acog.org/Patients/FAQs/Prenatal-Genetic-Screening-Tests?IsMobileSet=false. Accessed January 2017.